Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy in a Phase III trial in ...
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 LIBRETTO-432 clinical trial of ...
5don MSN
Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients
Eli Lilly and Co. LLY on Monday shared positive topline results from the Phase 3 LIBRETTO-432 clinical trial for Retevmo ...
US pharma major Eli Lilly today announced positive top-line results from the Phase III LIBRETTO-432 clinical trial of Retevmo ...
LIBRETTO-432 shows statistically significant event-free survival benefit in RET fusion-positive NSCLC after initial therapy.
Lilly's phase 3 LIBRETTO-432 trial of Retevmo an adjuvant therapy in early-stage RET fusion-positive lung cancer meets its primary endpoint: Indianapolis Tuesday, February 17, 202 ...
Entering text into the input field will update the search result below Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by ...
Jan 22 (Reuters) - Eli Lilly and Co's stomach cancer drug ramucirumab met its primary goal of improving overall survival in a late stage-study, extending the lives of patients for more than a month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results